{"id":"W4283392950","doi":"10.1097/01.hs9.0000847476.69621.cd","title":"P1152: RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH-222, A NOVEL CD22-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (R/R NHL)","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Pharmacokinetics; Antibody-drug conjugate; Internal medicine; Cmax; Refractory (planetary science); Phases of clinical research; Gastroenterology; Lymphoma; Oncology; Antibody; Pharmacology; Toxicity; Adverse effect; Monoclonal antibody; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008402198,0.0004179331,0.0008731701,0.0002005755,0.0002007899,0.00002461063,0.0002750997,0.00008394457,0.002370265],"category_scores_gemma":[0.0001012062,0.0003774044,0.00009227057,0.0007754774,0.0001327314,0.0001398453,0.0003439179,0.0006788909,0.000007767393],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003230551,"about_ca_system_score_gemma":0.0002803144,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001927125,"about_ca_topic_score_gemma":0.0001352934,"domain_scores_codex":[0.9958989,0.0003214949,0.001003268,0.000932212,0.001246748,0.0005973951],"domain_scores_gemma":[0.9979665,0.0004502654,0.0004091435,0.0006896376,0.0002073017,0.0002771195],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1388092,0.06623413,0.2821139,0.0005365031,0.0007302428,0.0009035453,0.02466263,0.0003568779,0.4495048,0.000002606267,0.003171927,0.03297361],"study_design_scores_gemma":[0.680592,0.0194296,0.2296651,0.0007027533,0.0005127135,0.00003401615,0.02321856,0.004491675,0.02049,0.00001242934,0.01953722,0.001313944],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9926269,0.0006287458,0.00001667828,0.00008173749,0.0001455757,0.002722356,0.00056025,0.00005380054,0.00316398],"genre_scores_gemma":[0.997069,0.00007361866,0.0003982096,0.0001329082,0.00008927034,0.0001039845,0.0005388419,0.0001173727,0.001476786],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5417828,"threshold_uncertainty_score":0.9998678,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0126925416239034,"score_gpt":0.2900373408021528,"score_spread":0.2773447991782494,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}